Incannex doses first patient in DReAMzz Phase 2 study of IHL-42X for sleep apnea

Incannex Healthcare Inc.

First patient dosed in DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea (OSA).
All 14 U.S. clinical trial sites have IRB approval; drug product manufactured and patient screening underway.
Builds on Phase 2 RePOSA results: statistically significant AHI reductions vs placebo, individual reductions up to 83%.
FDA granted Fast Track designation to IHL-42X program, supporting expedited development and review.
Study aims to optimize dose selection and inform design of planned Phase 3 development program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.